Blog Category

Financial

Biophytis announces completion of €5.3 million capital increase to fund its phase 2 trial in obesity

,

/

11 September 2026

Biophytis strengthens its financial position and extends its cash runway into Q1 2027

, , ,

/

31 August 2026

BIOPHYTIS PROVIDES AN UPDATE AND SHARE STRATEGIC DRIVERS SUPPORTING ITS HONG KONG JOINT VENTURE

, ,

/

3 August 2026

Biophytis announces the auditing of its 2025 financial statements and the resumption of trading in its stock

, , ,

/

29 July 2026

BIOPHYTIS REPORTS ITS PROVISIONAL FINANCIAL RESULTS AND PROVIDES ITS STRATEGIC OUTLOOK

, , ,

/

1 July 2026

BIOPHYTIS STRATEGIC UPDATE: JOINT VENTURE REGISTRATION FILING SUBMITTED IN HONG KONG

, ,

/

2 June 2026

BIOPHYTIS CHANGES ITS FINANCING AGREEMENT WITH HEXAGON CAPITAL FUND TO ENSURE ITS €2 MILLION FACILITY IS RENEWABLE

, , , ,

/

28 May 2026

Biophytis announces completion of over €2.0 million capital increase and the repayment of all variable price convertible debt

,

/

11 March 2026

Biophytis increases to €2 million the ceiling of its bond facility with Hexagon Capital Fund

,

/

28 February 2026

Biophytis enters strategic agreement in Asia and secures $20 million for launch of Phase 3 trial in sarcopenia

, ,

/

28 January 2026

Biophytis Reports First-Half 2025 Results and Provides Strategic Update

, , , ,

/

30 October 2025

Biophytis Secures Non-Dilutive Bond Financing Line of up to €1 Million

,

/

5 August 2025